Five Highlights From a Dramatic Year in European Health Stocks
- Huge Shire takeover, Healthineers spin-off among main events
- Trump’s war on drug pricing likely to remain in focus in 2019
This article is for subscribers only.
There was no shortage of drama in European health care in 2018.
Broadly speaking, the sector outperformed as pharma’s low-risk qualities attracted investors seeking havens when volatility spiked. That was despite President Donald Trump waging war against rising drug prices in the U.S.